CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments

1.3.1. By Therapeutic Class
1.3.2. By Type
1.3.3. By Formulation
1.3.4. By Distribution Channel
1.3.5. By Region
1.3.6. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets

3.3. Top player positioning, 2017
3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Increase in prevalence of arthritis
3.4.1.2. Growth in geriatric population
3.4.1.3. High demand for topical pain relief products by sportsperson
3.4.1.4. Lesser side effects caused by topical pain relief products as compared to oral medicines

3.4.2. Restraints

3.4.2.1. Topical pain relief sometimes cause skin irritants
3.4.2.2. Topical pain relief are characterized by unpleasant odor

3.4.3. Opportunities

3.4.3.1. Emergence of online pharmacy
3.4.3.2. Opportunities in emerging economies

3.4.4. Impact analyses

3.5. Patent analysis (2013-2018)

3.5.1. Patent analysis, by year
3.5.2. Patent analysis for U.S., by year

CHAPTER 4: TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS

4.1. Overview

4.1.1. Market size and forecast

4.2. Non-opioids

4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by type

4.2.2.1. Nonsteroidal anti-inflammatory drugs (NSAIDS)

4.2.2.1.1. Market size and forecast, by region

4.2.2.2. Methyl salicylates

4.2.2.2.1. Market size and forecast, by region

4.2.2.3. Capsaicin

4.2.2.3.1. Market size and forecast, by region

4.2.2.4. Lidocaine

4.2.2.4.1. Market size and forecast, by region

4.2.2.5. Other Non-Opioids

4.2.2.5.1. Market size and forecast, by region

4.2.3. Market size and forecast, by region
4.2.4. Market analysis, by country

4.3. Opioids

4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by type

4.3.2.1. Buprenorphine

4.3.2.1.1. Market size and forecast, by region

4.3.2.2. Fentanyl

4.3.2.2.1. Market size and forecast, by region

4.3.3. Market size and forecast, by region
4.3.4. Market analysis, by country

CHAPTER 5: TOPICAL PAIN RELIEF MARKET, BY FORMULATION

5.1. Overview

5.1.1. Market size and forecast

5.2. Cream

5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country

5.3. Gel

5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country

5.4. Spray

5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country

5.5. Patch

5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by country

5.6. Others

5.6.1. Market size and forecast, by region
5.6.2. Market analysis, by country

CHAPTER 6: TOPICAL PAIN RELIEF MARKET, BY TYPE

6.1. Overview

6.1.1. Market size and forecast

6.2. Prescription pain relief

6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country

6.3. Over-the-counter pain relief

6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country

CHAPTER 7: TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL

7.1. Overview

7.1.1. Market size and forecast

7.2. Pharmacies & drug stores

7.2.1. Market size and forecast, by region
7.2.2. Market analysis, by country

7.3. e-Commerce

7.3.1. Market size and forecast, by region
7.3.2. Market analysis, by country

7.4. Grocery stores

7.4.1. Market size and forecast, by region
7.4.2. Market analysis, by country

CHAPTER 8: TOPICAL PAIN RELIEF MARKET, BY REGION

8.1. Overview

8.1.1. Market size and forecast

8.2. North America

8.2.1. Key market trends, growth factors and opportunities
8.2.2. North America topical pain relief market, by country

8.2.2.1. U.S.

8.2.2.1.1. Market size and forecast, by therapeutic class
8.2.2.1.2. Market size and forecast, by formulation
8.2.2.1.3. Market size and forecast, by type
8.2.2.1.4. Market size and forecast, by distribution channel

8.2.2.2. Canada

8.2.2.2.1. Market size and forecast, by therapeutic class
8.2.2.2.2. Market size and forecast, by formulation
8.2.2.2.3. Market size and forecast, by type
8.2.2.2.4. Market size and forecast, by distribution channel

8.2.2.3. Mexico

8.2.2.3.1. Market size and forecast, by therapeutic class
8.2.2.3.2. Market size and forecast, by formulation
8.2.2.3.3. Market size and forecast, by type
8.2.2.3.4. Market size and forecast, by distribution channel

8.2.3. North America market size and forecast, by therapeutic class
8.2.4. North America market size and forecast, by formulation
8.2.5. North America market size and forecast, by type
8.2.6. North America market size and forecast, by distribution channel

8.3. Europe

8.3.1. Key market trends, growth factors and opportunities
8.3.2. Europe market size and forecast, by country

8.3.2.1. Germany

8.3.2.1.1. Market size and forecast, by therapeutic class
8.3.2.1.2. Market size and forecast, by formulation
8.3.2.1.3. Market size and forecast, by type
8.3.2.1.4. Market size and forecast, by distribution channel

8.3.2.2. France

8.3.2.2.1. Market size and forecast, by therapeutic class
8.3.2.2.2. Market size and forecast, by formulation
8.3.2.2.3. Market size and forecast, by type
8.3.2.2.4. Market size and forecast, by distribution channel

8.3.2.3. UK

8.3.2.3.1. Market size and forecast, by therapeutic class
8.3.2.3.2. Market size and forecast, by formulation
8.3.2.3.3. Market size and forecast, by type
8.3.2.3.4. Market size and forecast, by distribution channel

8.3.2.4. Italy

8.3.2.4.1. Market size and forecast, by therapeutic class
8.3.2.4.2. Market size and forecast, by formulation
8.3.2.4.3. Market size and forecast, by type
8.3.2.4.4. Market size and forecast, by distribution channel

8.3.2.5. Spain

8.3.2.5.1. Market size and forecast, by therapeutic class
8.3.2.5.2. Market size and forecast, by formulation
8.3.2.5.3. Market size and forecast, by type
8.3.2.5.4. Market size and forecast, by distribution channel

8.3.3. Rest of Europe

8.3.3.1.1. Market size and forecast, by therapeutic class
8.3.3.1.2. Market size and forecast, by formulation
8.3.3.1.3. Market size and forecast, by type
8.3.3.1.4. Market size and forecast, by distribution channel

8.3.4. Europe market size and forecast, by therapeutic class
8.3.5. Europe market size and forecast, by formulation
8.3.6. Europe market size and forecast, by type
8.3.7. Europe market size and forecast, by distribution channel

8.4. Asia-Pacific

8.4.1. Key market trends, growth factors and opportunities
8.4.2. Asia-Pacific market size and forecast, by country

8.4.2.1. Japan

8.4.2.1.1. Market size and forecast, by therapeutic class
8.4.2.1.2. Market size and forecast, by type
8.4.2.1.3. Market size and forecast, by type
8.4.2.1.4. Market size and forecast, by distribution channel

8.4.2.2. China

8.4.2.2.1. Market size and forecast, by therapeutic class
8.4.2.2.2. Market size and forecast, by formulation
8.4.2.2.3. Market size and forecast, by type
8.4.2.2.4. Market size and forecast, by distribution channel

8.4.2.3. India

8.4.2.3.1. Market size and forecast, by therapeutic class
8.4.2.3.2. Market size and forecast, by formulation
8.4.2.3.3. Market size and forecast, by type
8.4.2.3.4. Market size and forecast, by distribution channel

8.4.2.4. Australia

8.4.2.4.1. Market size and forecast, by therapeutic class
8.4.2.4.2. Market size and forecast, by formulation
8.4.2.4.3. Market size and forecast, by type
8.4.2.4.4. Market size and forecast, by distribution channel

8.4.2.5. South Korea

8.4.2.5.1. Market size and forecast, by therapeutic class
8.4.2.5.2. Market size and forecast, by formulation
8.4.2.5.3. Market size and forecast, by type
8.4.2.5.4. Market size and forecast, by distribution channel

8.4.2.6. Rest of Asia-Pacific

8.4.2.6.1. Market size and forecast, by therapeutic class
8.4.2.6.2. Market size and forecast, by formulation
8.4.2.6.3. Market size and forecast, by type
8.4.2.6.4. Market size and forecast, by distribution channel

8.4.3. Asia-Pacific market size and forecast, by therapeutic class
8.4.4. Asia-Pacific market size and forecast, by formulation
8.4.5. Asia-Pacific market size and forecast, by type
8.4.6. Asia-Pacific market size and forecast, by distribution channel

8.5. LAMEA

8.5.1. Key market trends, growth factors and opportunities
8.5.2. LAMEA market size and forecast, by country

8.5.2.1. Brazil

8.5.2.1.1. Market size and forecast, by therapeutic class
8.5.2.1.2. Market size and forecast, by formulation
8.5.2.1.3. Market size and forecast, by type
8.5.2.1.4. Market size and forecast, by distribution channel

8.5.2.2. Saudi Arabia

8.5.2.2.1. Market size and forecast, by therapeutic class
8.5.2.2.2. Market size and forecast, by formulation
8.5.2.2.3. Market size and forecast, by type
8.5.2.2.4. Market size and forecast, by distribution channel

8.5.2.3. South Africa

8.5.2.3.1. Market size and forecast, by therapeutic class
8.5.2.3.2. Market size and forecast, by formulation
8.5.2.3.3. Market size and forecast, by type
8.5.2.3.4. Market size and forecast, by distribution channel

8.5.2.4. Rest of LAMEA

8.5.2.4.1. Market size and forecast, by therapeutic class
8.5.2.4.2. Market size and forecast, by formulation
8.5.2.4.3. Market size and forecast, by type
8.5.2.4.4. Market size and forecast, by distribution channel

8.5.3. LAMEA market size and forecast, by therapeutic class
8.5.4. LAMEA market size and forecast, by formulation
8.5.5. LAMEA market size and forecast, by type
8.5.6. LAMEA market size and forecast, by distribution channel

CHAPTER 9: COMPANY PROFILES

9.1. AdvaCare Pharma

9.1.1. Company overview
9.1.2. Company snapshot
9.1.3. Operating business segments
9.1.4. Product Portfolio

9.2. GlaxoSmithKline plc.

9.2.1. Company overview
9.2.2. Company snapshot
9.2.3. Operating business segments
9.2.4. Product Portfolio
9.2.5. Business performance
9.2.6. Key strategic moves and developments

9.3. Johnson & Johnson

9.3.1. Company overview
9.3.2. Company snapshot
9.3.3. Operating business segments
9.3.4. Product Portfolio
9.3.5. Business performance

9.4. Nestl S.A.

9.4.1. Company overview
9.4.2. Company snapshot
9.4.3. Operating business segments
9.4.4. Product Portfolio
9.4.5. Business performance

9.5. Novartis AG

9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Operating business segments
9.5.4. Product Portfolio
9.5.5. Business performance

9.6. Pfizer Inc.

9.6.1. Company overview
9.6.2. Company snapshot
9.6.3. Operating business segments
9.6.4. Product Portfolio
9.6.5. Business performance

9.7. Reckitt Benckiser Group plc

9.7.1. Company overview
9.7.2. Company snapshot
9.7.3. Operating business segments
9.7.4. Product Portfolio
9.7.5. Business performance

9.8. Sanofi

9.8.1. Company overview
9.8.2. Company snapshot
9.8.3. Operating business segments
9.8.4. Product Portfolio
9.8.5. Business performance
9.8.6. Key strategic moves and developments

9.9. Sun Pharmaceutical Industries Ltd.

9.9.1. Company overview
9.9.2. Company snapshot
9.9.3. Operating business segments
9.9.4. Product Portfolio
9.9.5. Business performance
9.9.6. Key strategic moves and developments

9.10. Topical BioMedics, Inc.

9.10.1. Company overview
9.10.2. Company snapshot
9.10.3. Operating business segments
9.10.4. Product Portfolio
9.10.5. Key strategic moves and developments